drugset / Trial / NCT01857817
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.
Timeline
- Start
- 2013-06
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etodolac | Unknown | 680 mg | Oral |
| Subject | Propranolol | Small molecule | 66 mg | Oral |